JP2015509505A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015509505A5 JP2015509505A5 JP2014558898A JP2014558898A JP2015509505A5 JP 2015509505 A5 JP2015509505 A5 JP 2015509505A5 JP 2014558898 A JP2014558898 A JP 2014558898A JP 2014558898 A JP2014558898 A JP 2014558898A JP 2015509505 A5 JP2015509505 A5 JP 2015509505A5
- Authority
- JP
- Japan
- Prior art keywords
- lipid
- particle
- composition
- item
- optionally substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000002632 lipids Chemical class 0.000 claims description 82
- 239000002245 particle Substances 0.000 claims description 59
- 239000000203 mixture Substances 0.000 claims description 20
- 125000000217 alkyl group Chemical group 0.000 claims description 16
- 239000003814 drug Substances 0.000 claims description 14
- 229940124597 therapeutic agent Drugs 0.000 claims description 14
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 12
- 241000124008 Mammalia Species 0.000 claims description 11
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 10
- 239000004055 small Interfering RNA Substances 0.000 claims description 10
- -1 dimethylamino, diethylamino Chemical group 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 230000002452 interceptive effect Effects 0.000 claims description 8
- 108020004459 Small interfering RNA Proteins 0.000 claims description 6
- 235000012000 cholesterol Nutrition 0.000 claims description 6
- 150000003904 phospholipids Chemical class 0.000 claims description 6
- 229920006395 saturated elastomer Polymers 0.000 claims description 6
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 claims description 4
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 claims description 4
- 239000002202 Polyethylene glycol Substances 0.000 claims description 4
- 108091027967 Small hairpin RNA Proteins 0.000 claims description 4
- 230000002776 aggregation Effects 0.000 claims description 4
- 238000004220 aggregation Methods 0.000 claims description 4
- 150000001408 amides Chemical class 0.000 claims description 4
- 150000004657 carbamic acid derivatives Chemical class 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 208000035475 disorder Diseases 0.000 claims description 4
- 150000002148 esters Chemical class 0.000 claims description 4
- 108091070501 miRNA Proteins 0.000 claims description 4
- 239000002679 microRNA Substances 0.000 claims description 4
- 108020004707 nucleic acids Proteins 0.000 claims description 4
- 102000039446 nucleic acids Human genes 0.000 claims description 4
- 150000007523 nucleic acids Chemical group 0.000 claims description 4
- 229920001223 polyethylene glycol Polymers 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 4
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims description 2
- 208000036142 Viral infection Diseases 0.000 claims description 2
- 125000003282 alkyl amino group Chemical group 0.000 claims description 2
- 150000001841 cholesterols Chemical class 0.000 claims description 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 2
- 125000001033 ether group Chemical group 0.000 claims description 2
- 150000002170 ethers Chemical class 0.000 claims description 2
- 230000002209 hydrophobic effect Effects 0.000 claims description 2
- 238000001727 in vivo Methods 0.000 claims description 2
- 238000007918 intramuscular administration Methods 0.000 claims description 2
- 238000007912 intraperitoneal administration Methods 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000019423 liver disease Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 210000002966 serum Anatomy 0.000 claims description 2
- 238000007920 subcutaneous administration Methods 0.000 claims description 2
- 239000000758 substrate Substances 0.000 claims description 2
- 230000009385 viral infection Effects 0.000 claims description 2
- 238000000034 method Methods 0.000 description 11
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261602990P | 2012-02-24 | 2012-02-24 | |
| US61/602,990 | 2012-02-24 | ||
| PCT/US2013/027469 WO2013126803A1 (en) | 2012-02-24 | 2013-02-22 | Trialkyl cationic lipids and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017236756A Division JP6789918B2 (ja) | 2012-02-24 | 2017-12-11 | トリアルキルカチオン性脂質およびその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015509505A JP2015509505A (ja) | 2015-03-30 |
| JP2015509505A5 true JP2015509505A5 (enExample) | 2015-12-10 |
| JP6275655B2 JP6275655B2 (ja) | 2018-02-07 |
Family
ID=47884528
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014558898A Active JP6275655B2 (ja) | 2012-02-24 | 2013-02-22 | トリアルキルカチオン性脂質およびその使用方法 |
| JP2017236756A Active JP6789918B2 (ja) | 2012-02-24 | 2017-12-11 | トリアルキルカチオン性脂質およびその使用方法 |
| JP2020184356A Active JP7110297B2 (ja) | 2012-02-24 | 2020-11-04 | トリアルキルカチオン性脂質およびその使用方法 |
| JP2022115626A Pending JP2022140533A (ja) | 2012-02-24 | 2022-07-20 | トリアルキルカチオン性脂質およびその使用方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017236756A Active JP6789918B2 (ja) | 2012-02-24 | 2017-12-11 | トリアルキルカチオン性脂質およびその使用方法 |
| JP2020184356A Active JP7110297B2 (ja) | 2012-02-24 | 2020-11-04 | トリアルキルカチオン性脂質およびその使用方法 |
| JP2022115626A Pending JP2022140533A (ja) | 2012-02-24 | 2022-07-20 | トリアルキルカチオン性脂質およびその使用方法 |
Country Status (27)
| Country | Link |
|---|---|
| US (4) | US9352042B2 (enExample) |
| EP (3) | EP3473611B1 (enExample) |
| JP (4) | JP6275655B2 (enExample) |
| KR (4) | KR102384791B1 (enExample) |
| CN (2) | CN110003030A (enExample) |
| AU (1) | AU2013222179B2 (enExample) |
| BR (1) | BR112014020824B1 (enExample) |
| CA (1) | CA2865412C (enExample) |
| CY (1) | CY1121232T1 (enExample) |
| DK (1) | DK2817287T3 (enExample) |
| ES (2) | ES2702874T3 (enExample) |
| HR (1) | HRP20182156T1 (enExample) |
| HU (1) | HUE041494T2 (enExample) |
| IL (3) | IL234266B (enExample) |
| LT (1) | LT2817287T (enExample) |
| MX (3) | MX356904B (enExample) |
| NZ (1) | NZ700075A (enExample) |
| PH (1) | PH12014501901B1 (enExample) |
| PL (1) | PL2817287T3 (enExample) |
| PT (1) | PT2817287T (enExample) |
| RS (1) | RS58077B1 (enExample) |
| RU (2) | RU2718053C2 (enExample) |
| SG (1) | SG11201405157PA (enExample) |
| SI (1) | SI2817287T1 (enExample) |
| UA (1) | UA120026C2 (enExample) |
| WO (1) | WO2013126803A1 (enExample) |
| ZA (1) | ZA201406896B (enExample) |
Families Citing this family (231)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3338765T1 (sl) | 2009-12-01 | 2019-05-31 | Translate Bio, Inc. | Derivat steroida za dostavo MRNA pri humanih genetskih boleznih |
| US8853377B2 (en) | 2010-11-30 | 2014-10-07 | Shire Human Genetic Therapies, Inc. | mRNA for use in treatment of human genetic diseases |
| WO2012170930A1 (en) | 2011-06-08 | 2012-12-13 | Shire Human Genetic Therapies, Inc | Lipid nanoparticle compositions and methods for mrna delivery |
| CA2838063C (en) | 2011-06-08 | 2023-07-11 | Shire Human Genetic Therapies, Inc. | Cleavable lipids |
| AU2013222179B2 (en) * | 2012-02-24 | 2017-08-24 | Arbutus Biopharma Corporat ion | Trialkyl cationic lipids and methods of use thereof |
| ES2858523T3 (es) | 2012-03-29 | 2021-09-30 | Translate Bio Inc | Nanopartículas neutras derivadas de lípidos |
| BR112014024131A2 (pt) | 2012-03-29 | 2017-07-25 | Shire Human Genetic Therapies | lipídios catiônicos ionizáveis |
| WO2013185067A1 (en) | 2012-06-08 | 2013-12-12 | Shire Human Genetic Therapies, Inc. | Nuclease resistant polynucleotides and uses thereof |
| HK1208618A1 (en) | 2012-06-08 | 2016-03-11 | 夏尔人类遗传性治疗公司 | Pulmonary delivery of mrna to non-lung target cells |
| PL2970456T3 (pl) | 2013-03-14 | 2022-01-31 | Translate Bio, Inc. | Sposoby i kompozycje do dostarczania przeciwciał kodowanych mrna |
| MX393573B (es) | 2013-03-14 | 2025-03-21 | Shire Human Genetic Therapies | Composiciones de acido ribonucleico mensajero del regulador transmembrana de fibrosis quistica y metodos y usos relacionados |
| US10258698B2 (en) | 2013-03-14 | 2019-04-16 | Modernatx, Inc. | Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions |
| KR20150128687A (ko) | 2013-03-14 | 2015-11-18 | 샤이어 휴먼 지네틱 테라피즈 인크. | 메신저 rna의 정제 방법 |
| EP3757570B1 (en) | 2013-03-15 | 2023-10-11 | Translate Bio, Inc. | Synergistic enhancement of the delivery of nucleic acids via blended formulations |
| CN105555757A (zh) * | 2013-07-23 | 2016-05-04 | 普洛体维生物治疗公司 | 用于递送信使rna的组合物和方法 |
| WO2015034925A1 (en) | 2013-09-03 | 2015-03-12 | Moderna Therapeutics, Inc. | Circular polynucleotides |
| KR20160067219A (ko) | 2013-10-03 | 2016-06-13 | 모더나 세라퓨틱스, 인코포레이티드 | 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드 |
| AU2014340149B2 (en) | 2013-10-22 | 2020-12-24 | Shire Human Genetic Therapies, Inc. | CNS delivery of mRNA and uses thereof |
| CA2928078A1 (en) | 2013-10-22 | 2015-04-30 | Shire Human Genetic Therapies, Inc. | Lipid formulations for delivery of messenger rna |
| JP6608815B2 (ja) | 2013-10-22 | 2019-11-20 | トランスレイト バイオ， インコーポレイテッド | アルギニノコハク酸合成酵素欠損症のｍＲＮＡ治療 |
| EP3574923A1 (en) | 2013-10-22 | 2019-12-04 | Translate Bio, Inc. | Mrna therapy for phenylketonuria |
| EP3636742B1 (en) | 2014-04-25 | 2025-11-05 | Translate Bio, Inc. | Methods for purification of messenger rna |
| CA2949106C (en) | 2014-05-30 | 2023-10-24 | Shire Human Genetic Therapies, Inc. | Biodegradable lipids for delivery of nucleic acids |
| KR102387898B1 (ko) | 2014-06-24 | 2022-04-15 | 샤이어 휴먼 지네틱 테라피즈 인크. | 핵산의 전달용 입체화학적으로 풍부한 조성물 |
| WO2015199952A1 (en) | 2014-06-25 | 2015-12-30 | Acuitas Therapeutics Inc. | Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids |
| WO2016004318A1 (en) | 2014-07-02 | 2016-01-07 | Shire Human Genetic Therapies, Inc. | Encapsulation of messenger rna |
| WO2016011226A1 (en) | 2014-07-16 | 2016-01-21 | Moderna Therapeutics, Inc. | Chimeric polynucleotides |
| US20170210788A1 (en) | 2014-07-23 | 2017-07-27 | Modernatx, Inc. | Modified polynucleotides for the production of intrabodies |
| ES2799409T3 (es) | 2014-08-07 | 2020-12-17 | Takeda Pharmaceuticals Co | Lípido catiónico |
| US9339029B2 (en) * | 2014-09-04 | 2016-05-17 | Preceres Inc. | Hydrazinyl lipidoids and uses thereof |
| MA56412A (fr) | 2014-12-05 | 2022-05-04 | Translate Bio Inc | Thérapie par l'arn messager pour le traitement des maladies articulaires |
| JP2018509406A (ja) * | 2015-03-11 | 2018-04-05 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | フィロウイルス感染症の処置のための方法及び医薬組成物 |
| AU2016233135B2 (en) | 2015-03-19 | 2021-07-08 | Translate Bio, Inc. | mRNA therapy for pompe disease |
| CA2984125A1 (en) | 2015-04-27 | 2016-11-03 | The Trustees Of The University Of Pennsylvania | Nucleoside-modified rna for inducing an adaptive immune response |
| HUE067372T2 (hu) * | 2015-06-29 | 2024-10-28 | Acuitas Therapeutics Inc | Lipidek és nanoszemcsés lipid formulázások nukleinsavak beadására |
| JP6948313B6 (ja) | 2015-09-17 | 2022-01-14 | モデルナティエックス インコーポレイテッド | 治療剤の細胞内送達のための化合物および組成物 |
| CN114686548A (zh) | 2015-10-14 | 2022-07-01 | 川斯勒佰尔公司 | 用于增强生产的rna相关酶的修饰 |
| WO2017070613A1 (en) | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| IL286515B2 (en) | 2015-10-28 | 2024-02-01 | Acuitas Therapeutics Inc | Novel lipids and nanoparticle formulations of lipids for delivery of nucleic acids |
| EP3394030B2 (en) | 2015-12-22 | 2025-02-12 | ModernaTX, Inc. | Compounds and compositions for intracellular delivery of agents |
| LT3394093T (lt) | 2015-12-23 | 2022-04-25 | Modernatx, Inc. | Ox40 ligandus koduojančių polinukleotidų naudojimo būdai |
| MA43587A (fr) | 2016-01-10 | 2018-11-14 | Modernatx Inc | Arnm thérapeutiques codant pour des anticorps anti-ctla-4 |
| EP3440206B1 (en) | 2016-04-08 | 2020-10-28 | Translate Bio, Inc. | Multimeric coding nucleic acid and uses thereof |
| US12128113B2 (en) | 2016-05-18 | 2024-10-29 | Modernatx, Inc. | Polynucleotides encoding JAGGED1 for the treatment of Alagille syndrome |
| AU2017283479B2 (en) | 2016-06-13 | 2023-08-17 | Translate Bio, Inc. | Messenger RNA therapy for the treatment of ornithine transcarbamylase deficiency |
| EP3478838A1 (en) | 2016-06-30 | 2019-05-08 | Arbutus Biopharma Corporation | Compositions and methods for delivering messenger rna |
| EP3538067A1 (en) | 2016-11-08 | 2019-09-18 | Modernatx, Inc. | Stabilized formulations of lipid nanoparticles |
| US11241490B2 (en) | 2017-01-11 | 2022-02-08 | The Trustees Of The University Of Pennsylvania | Nucleoside-modified RNA for inducing an immune response against zika virus |
| EP3585417B1 (en) | 2017-02-27 | 2023-02-22 | Translate Bio, Inc. | Method of making a codon-optimized cftr mrna |
| DK3596041T3 (da) | 2017-03-15 | 2023-01-23 | Modernatx Inc | Forbindelse og sammensætninger til intracellulær afgivelse af terapeutiske midler |
| WO2018170336A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Lipid nanoparticle formulation |
| WO2018170256A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Herpes simplex virus vaccine |
| EP3601576A1 (en) | 2017-03-24 | 2020-02-05 | CureVac AG | Nucleic acids encoding crispr-associated proteins and uses thereof |
| WO2018191657A1 (en) | 2017-04-13 | 2018-10-18 | Acuitas Therapeutics, Inc. | Lipids for delivery of active agents |
| ES2981244T3 (es) | 2017-04-28 | 2024-10-07 | Acuitas Therapeutics Inc | Novedosas formulaciones de nanopartículas de lípidos de carbonilo y lípidos para la administración de ácidos nucleicos |
| FR3066115B1 (fr) * | 2017-05-10 | 2019-06-28 | Universite de Bordeaux | Comprimes de vecteurs d'acides nucleiques |
| AU2018268859B2 (en) | 2017-05-16 | 2024-07-25 | Translate Bio, Inc. | Treatment of cystic fibrosis by delivery of codon-optimized mrna encoding CFTR |
| EP3625246A1 (en) | 2017-05-18 | 2020-03-25 | ModernaTX, Inc. | Polynucleotides encoding tethered interleukin-12 (il12) polypeptides and uses thereof |
| EP3638678B1 (en) | 2017-06-14 | 2025-12-03 | ModernaTX, Inc. | Compounds and compositions for intracellular delivery of agents |
| EP3638292A1 (en) | 2017-06-14 | 2020-04-22 | ModernaTX, Inc. | Polynucleotides encoding coagulation factor viii |
| MA49421A (fr) | 2017-06-15 | 2020-04-22 | Modernatx Inc | Formulations d'arn |
| US20210228738A1 (en) | 2017-07-17 | 2021-07-29 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins |
| US11639329B2 (en) | 2017-08-16 | 2023-05-02 | Acuitas Therapeutics, Inc. | Lipids for use in lipid nanoparticle formulations |
| WO2019036000A1 (en) | 2017-08-17 | 2019-02-21 | Acuitas Therapeutics, Inc. | LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS |
| US11542225B2 (en) | 2017-08-17 | 2023-01-03 | Acuitas Therapeutics, Inc. | Lipids for use in lipid nanoparticle formulations |
| US11524932B2 (en) | 2017-08-17 | 2022-12-13 | Acuitas Therapeutics, Inc. | Lipids for use in lipid nanoparticle formulations |
| US11866696B2 (en) | 2017-08-18 | 2024-01-09 | Modernatx, Inc. | Analytical HPLC methods |
| CA3073211A1 (en) | 2017-08-31 | 2019-03-07 | Modernatx, Inc. | Methods of making lipid nanoparticles |
| MA51306A (fr) | 2017-12-20 | 2020-10-28 | Translate Bio Inc | Compositions et procédés améliorés pour le traitement du déficit en ornithine transcarbamylase |
| BR112020013201A2 (pt) * | 2017-12-27 | 2020-12-01 | Takeda Pharmaceutical Company Limited | nanopartícula lipídica, medicamento, métodos para expressar um receptor, para prevenir ou tratar câncer e para produzir um medicamento, uso da nanopartícula lipídica e do imunócito ex vivo, composição, imunócito ex vivo, e, célula ex vivo |
| FI3835287T3 (fi) | 2018-08-10 | 2024-12-03 | Takeda Pharmaceuticals Co | Kationinen lipidi |
| US11174500B2 (en) | 2018-08-24 | 2021-11-16 | Translate Bio, Inc. | Methods for purification of messenger RNA |
| WO2020061284A1 (en) | 2018-09-19 | 2020-03-26 | Modernatx, Inc. | Peg lipids and uses thereof |
| US12263248B2 (en) | 2018-09-19 | 2025-04-01 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of therapeutic agents |
| JP7640452B2 (ja) | 2018-09-19 | 2025-03-05 | モデルナティエックス インコーポレイテッド | 高純度ｐｅｇ脂質及びそれらの使用 |
| US12090235B2 (en) | 2018-09-20 | 2024-09-17 | Modernatx, Inc. | Preparation of lipid nanoparticles and methods of administration thereof |
| US12329857B2 (en) | 2018-09-21 | 2025-06-17 | Acuitas Therapeutics, Inc. | Systems and methods for manufacturing lipid nanoparticles and liposomes |
| CA3114699A1 (en) | 2018-10-09 | 2020-04-16 | The University Of British Columbia | Compositions and systems comprising transfection-competent vesicles free of organic-solvents and detergents and methods related thereto |
| KR20210080435A (ko) | 2018-10-18 | 2021-06-30 | 다케다 야쿠힌 고교 가부시키가이샤 | T 세포의 활성화/증식을 위한 방법 |
| MX2021005389A (es) * | 2018-11-09 | 2021-07-21 | Arbutus Biopharma Corp | Formulaciones de nanoparticulas lipidicas. |
| CN113728101A (zh) * | 2018-11-09 | 2021-11-30 | 阿布特斯生物制药公司 | 脂质纳米颗粒制剂 |
| WO2020106946A1 (en) | 2018-11-21 | 2020-05-28 | Translate Bio, Inc. | TREATMENT OF CYSTIC FIBROSIS BY DELIVERY OF NEBULIZED mRNA ENCODING CFTR |
| MA55321A (fr) | 2019-03-15 | 2022-01-19 | Modernatx Inc | Vaccins à base d'arn contre le vih |
| WO2020255010A1 (en) | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Combination of recombinant interleukin 12 construct and hepatitis b virus (hbv) vaccines |
| US20220296703A1 (en) | 2019-06-18 | 2022-09-22 | Janssen Sciences Ireland Unlimited Company | Cobmination of hepatitis b virus (hbv) vaccines and anti-pd-1 or anti-pd-l1 antibody |
| WO2020255014A1 (en) | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Recombinant interleukin 12 construct and uses thereof |
| EP3986460A2 (en) | 2019-06-18 | 2022-04-27 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and anti-pd-1 antibody |
| US20220305117A1 (en) | 2019-06-18 | 2022-09-29 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and hbv-targeting rnai |
| WO2020255062A1 (en) | 2019-06-20 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Lipid nanoparticle or liposome delivery of hepatitis b virus (hbv) vaccines |
| EP3990441A4 (en) * | 2019-06-29 | 2022-08-24 | Precision Nanosystems Inc | Ionizable lipids for nucleic acid delivery |
| CA3147875A1 (en) | 2019-07-19 | 2021-01-28 | Flagship Pioneering Innovations Vi, Llc | Recombinase compositions and methods of use |
| KR20220101077A (ko) | 2019-09-19 | 2022-07-19 | 모더나티엑스, 인크. | 치료제의 세포내 전달을 위한 분지형 꼬리 지질 화합물 및 조성물 |
| KR20220103923A (ko) * | 2019-09-19 | 2022-07-25 | 모더나티엑스, 인크. | 치료제의 세포내 전달을 위한 신규한 헤드기 지질 화합물 및 조성물 |
| CN114391040A (zh) | 2019-09-23 | 2022-04-22 | 欧米茄治疗公司 | 用于调节载脂蛋白b(apob)基因表达的组合物和方法 |
| AU2020352552A1 (en) | 2019-09-23 | 2022-03-17 | Omega Therapeutics, Inc. | Compositions and methods for modulating hepatocyte nuclear factor 4-alpha (HNF4α) gene expression |
| WO2021081225A1 (en) * | 2019-10-22 | 2021-04-29 | Genevant Sciences Gmbh | Ornithine transcarbamylase (otc) constructs and methods of using the same |
| WO2021183720A1 (en) | 2020-03-11 | 2021-09-16 | Omega Therapeutics, Inc. | Compositions and methods for modulating forkhead box p3 (foxp3) gene expression |
| US20230150926A1 (en) * | 2020-03-17 | 2023-05-18 | Genevant Sciences Gmbh | Cationic lipids for lipid nanoparticle delivery of therapeutics to hepatic stellate cells |
| KR20230003477A (ko) | 2020-03-24 | 2023-01-06 | 제너레이션 바이오 컴퍼니 | 비-바이러스성 dna 벡터 및 인자 ix 치료제 발현을 위한 이의 용도 |
| CA3172591A1 (en) | 2020-03-24 | 2021-09-30 | Douglas Anthony KERR | Non-viral dna vectors and uses thereof for expressing gaucher therapeutics |
| AU2021275223A1 (en) | 2020-05-20 | 2023-02-02 | Flagship Pioneering Innovations Vi, Llc. | Coronavirus antigen compositions and their uses |
| TW202208629A (zh) | 2020-05-20 | 2022-03-01 | 美商旗艦先鋒創新有限責任公司 | 免疫原性組成物及其用途 |
| AU2021281453A1 (en) | 2020-05-29 | 2022-11-17 | Flagship Pioneering Innovations Vi, Llc. | Trem compositions and methods relating thereto |
| EP4158031A1 (en) | 2020-05-29 | 2023-04-05 | Flagship Pioneering Innovations VI, LLC | Trem compositions and methods relating thereto |
| PH12023550030A1 (en) | 2020-07-08 | 2024-03-11 | Janssen Sciences Ireland Unlimited Co | Rna replicon vaccines against hbv |
| CN116096702A (zh) | 2020-07-16 | 2023-05-09 | 爱康泰生治疗公司 | 用于脂质纳米颗粒的阳离子脂质 |
| US20230272432A1 (en) | 2020-07-27 | 2023-08-31 | Anjarium Biosciences Ag | Compositions of dna molecules, methods of making therefor, and methods of use thereof |
| JP2023538260A (ja) | 2020-08-06 | 2023-09-07 | モダーナティエックス・インコーポレイテッド | ペイロード分子を気道上皮に送達するための組成物 |
| CA3193746A1 (en) | 2020-09-03 | 2022-03-10 | Flagship Pioneering Innovations Vi, Llc | Immunogenic compositions and uses thereof |
| US20230372491A1 (en) * | 2020-10-12 | 2023-11-23 | The Regents Of The University Of California | Endosomal escape domains for delivery of macromolecules into cells |
| IL301890A (en) | 2020-10-14 | 2023-06-01 | George Mason Res Foundation Inc | Ionizable lipids and methods of manufacture and use thereof |
| TW202245809A (zh) | 2020-12-18 | 2022-12-01 | 美商詹森藥物公司 | 用於治療b型肝炎病毒感染之組合療法 |
| WO2022133344A1 (en) | 2020-12-18 | 2022-06-23 | Genevant Sciences Gmbh | Peg lipids and lipid nanoparticles |
| MX2023007630A (es) | 2020-12-23 | 2023-08-25 | Flagship Pioneering Innovations Vi Llc | Composiciones de trem modificadas y usos de las mismas. |
| AU2021412833A1 (en) | 2020-12-28 | 2023-07-06 | Arcturus Therapeutics, Inc. | Transcription activator-like effector nucleases (talens) targeting hbv |
| CN116887812A (zh) | 2021-02-26 | 2023-10-13 | 埃泽瑞斯公司 | 用于气溶胶形成的制剂以及用于递送核酸的气溶胶 |
| US11952461B2 (en) | 2021-03-22 | 2024-04-09 | Sunbio, Inc. | Siloxy polyethylene glycol and derivatives thereof |
| KR20230165276A (ko) | 2021-03-31 | 2023-12-05 | 플래그쉽 파이어니어링 이노베이션스 브이, 인크. | 타노트랜스미션 폴리펩티드 및 암의 치료에서의 이의 용도 |
| CN115197079A (zh) * | 2021-04-08 | 2022-10-18 | 厦门赛诺邦格生物科技股份有限公司 | 一种聚乙二醇化脂质及其修饰的脂质体、含该脂质体的药物组合物及其制剂和应用 |
| KR20240012370A (ko) | 2021-04-20 | 2024-01-29 | 안자리움 바이오사이언시스 아게 | 아밀로-알파-1, 6-글루코시다제, 4-알파-글루카노트랜스퍼라제를 인코딩하는 dna 분자의 조성물, 이를 제조하는 방법 및 이를 사용하는 방법 |
| KR20240011714A (ko) | 2021-04-27 | 2024-01-26 | 제너레이션 바이오 컴퍼니 | 치료용 항체를 발현하는 비바이러스성 dna 벡터 및 이의 용도 |
| US20240216535A1 (en) | 2021-04-27 | 2024-07-04 | Generation Bio Co. | Non-viral dna vectors expressing anti-coronavirus antibodies and uses thereof |
| JP2024515317A (ja) | 2021-04-28 | 2024-04-08 | ジェネバント サイエンシズ ゲーエムベーハー | ｍＲＮＡ送達構築物およびそれを使用する方法 |
| CN112979483B (zh) * | 2021-05-14 | 2021-08-06 | 苏州艾博生物科技有限公司 | 一种阳离子脂质化合物、包含其的组合物及应用 |
| WO2023283359A2 (en) | 2021-07-07 | 2023-01-12 | Omega Therapeutics, Inc. | Compositions and methods for modulating secreted frizzled receptor protein 1 (sfrp1) gene expression |
| AU2022315530A1 (en) | 2021-07-20 | 2024-01-18 | Ags Therapeutics Sas | Extracellular vesicles from microalgae, their preparation, and uses |
| US20240336945A1 (en) | 2021-07-26 | 2024-10-10 | Flagship Pioneering Innovations Vi, Llc | Trem compositions and uses thereof |
| JP2024534428A (ja) | 2021-09-17 | 2024-09-20 | フラッグシップ パイオニアリング イノベーションズ シックス，エルエルシー | 環状ポリリボヌクレオチドを生成するための組成物及び方法 |
| CA3235625A1 (en) | 2021-10-18 | 2023-04-27 | Flagship Pioneering Innovations Vi, Llc | Compositions and methods for purifying polyribonucleotides |
| MX2024005521A (es) | 2021-11-08 | 2024-05-21 | Orna Therapeutics Inc | Composiciones de nanoparticulas de lipidos para la administracion de polinucleotidos circulares. |
| CN118829423A (zh) | 2021-11-12 | 2024-10-22 | 摩登纳特斯有限公司 | 用于将有效载荷分子递送至气道上皮的组合物 |
| JP2024541466A (ja) | 2021-11-24 | 2024-11-08 | フラッグシップ パイオニアリング イノベーションズ シックス，エルエルシー | 水痘帯状疱疹ウイルス免疫原組成物及びその使用 |
| CN118900845A (zh) | 2021-11-24 | 2024-11-05 | 旗舰创业创新六公司 | 冠状病毒免疫原组合物及其用途 |
| WO2023097003A2 (en) | 2021-11-24 | 2023-06-01 | Flagship Pioneering Innovations Vi, Llc | Immunogenic compositions and their uses |
| EP4448485A2 (en) | 2021-12-16 | 2024-10-23 | Acuitas Therapeutics, Inc. | Lipids for use in lipid nanoparticle formulations |
| KR20240118174A (ko) | 2021-12-17 | 2024-08-02 | 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 | 변성 조건 하에서의 원형 rna의 풍부화를 위한 방법 |
| CN118679254A (zh) | 2021-12-22 | 2024-09-20 | 旗舰创业创新六公司 | 用于纯化多核糖核苷酸的组合物和方法 |
| AU2022420620A1 (en) | 2021-12-23 | 2024-07-04 | Flagship Pioneering Innovations Vi, Llc | Circular polyribonucleotides encoding antifusogenic polypeptides |
| CN114957027B (zh) * | 2022-01-13 | 2023-05-19 | 北京悦康科创医药科技股份有限公司 | 一种阳离子脂质化合物、包含其的组合物及用途 |
| EP4463475A2 (en) | 2022-01-14 | 2024-11-20 | Anjarium Biosciences AG | Compositions of dna molecules encoding factor viii, methods of making thereof, and methods of use thereof |
| WO2023144127A1 (en) | 2022-01-31 | 2023-08-03 | Ags Therapeutics Sas | Extracellular vesicles from microalgae, their biodistribution upon administration, and uses |
| WO2023154818A1 (en) | 2022-02-09 | 2023-08-17 | Modernatx, Inc. | Mucosal administration methods and formulations |
| WO2023161350A1 (en) | 2022-02-24 | 2023-08-31 | Io Biotech Aps | Nucleotide delivery of cancer therapy |
| US20250250227A1 (en) * | 2022-02-28 | 2025-08-07 | Shenzhen Shenxin Biotechnology Co., Ltd. | Amino lipid compound, preparation method therefor, composition thereof and use thereof |
| JP2025509607A (ja) | 2022-03-14 | 2025-04-11 | ジェネレーション バイオ カンパニー | 異種プライムブーストワクチン組成物及び使用の方法 |
| CN114380724B (zh) * | 2022-03-23 | 2022-05-24 | 深圳市瑞吉生物科技有限公司 | 用于递送核酸的阳离子脂质化合物和组合物及用途 |
| KR20240166554A (ko) | 2022-03-25 | 2024-11-26 | 세일 바이오메디슨스, 인크. | 신규한 이온화 가능 지질 및 지질 나노입자, 및 이를 사용하는 방법 |
| EP4504252A2 (en) | 2022-04-08 | 2025-02-12 | Flagship Pioneering Innovations VII, LLC | Vaccines and related methods |
| CN114685784B (zh) * | 2022-04-26 | 2023-09-15 | 北京清科胜因生物科技有限公司 | 一种用于核酸递送的聚(2-噁唑啉)脂质与脂质纳米颗粒及应用 |
| CN115626983A (zh) * | 2022-04-27 | 2023-01-20 | 北京清科胜因生物科技有限公司 | 一种聚(2-噁唑啉)脂质及脂质纳米颗粒 |
| WO2023220083A1 (en) | 2022-05-09 | 2023-11-16 | Flagship Pioneering Innovations Vi, Llc | Trem compositions and methods of use for treating proliferative disorders |
| JP2025516638A (ja) | 2022-05-13 | 2025-05-30 | フラッグシップ パイオニアリング イノベーションズ セブン，エルエルシー | 二本鎖ｄｎａ組成物及び関連する方法 |
| WO2023218420A1 (en) | 2022-05-13 | 2023-11-16 | Janssen Pharmaceuticals, Inc. | Mrna compositions for inducing latent hiv-1 reversal |
| WO2023233290A1 (en) | 2022-05-31 | 2023-12-07 | Janssen Sciences Ireland Unlimited Company | Rnai agents targeting pd-l1 |
| CN114940756B (zh) * | 2022-06-02 | 2023-11-07 | 北京清科胜因生物科技有限公司 | 一种聚（2-噁唑啉）脂质与脂质纳米颗粒及应用 |
| WO2023232976A1 (en) | 2022-06-03 | 2023-12-07 | Ags Therapeutics Sas | Extracellular vesicles from genetically-modified microalgae containing endogenously-loaded cargo, their preparation, and uses |
| CA3258303A1 (en) | 2022-06-07 | 2023-12-14 | Generation Bio Co | Compositions of lipid nanoparticles and their uses |
| CN117263818A (zh) * | 2022-06-14 | 2023-12-22 | 杭州高田生物医药有限公司 | 阳离子脂质化合物及其制备方法和应用 |
| EP4544043A1 (en) | 2022-06-22 | 2025-04-30 | Flagship Pioneering Innovations VI, LLC | Compositions of modified trems and uses thereof |
| AU2023320333A1 (en) | 2022-08-01 | 2025-01-16 | Flagship Pioneering Innovations Vii, Llc | Immunomodulatory proteins and related methods |
| WO2024035952A1 (en) | 2022-08-12 | 2024-02-15 | Remix Therapeutics Inc. | Methods and compositions for modulating splicing at alternative splice sites |
| WO2024040222A1 (en) | 2022-08-19 | 2024-02-22 | Generation Bio Co. | Cleavable closed-ended dna (cedna) and methods of use thereof |
| EP4327829A1 (en) | 2022-08-26 | 2024-02-28 | Ethris GmbH | Stabilization of lipid or lipidoid nanoparticle suspensions |
| CN120129532A (zh) | 2022-08-26 | 2025-06-10 | 埃泽瑞斯公司 | 稳定的脂质或类脂质纳米颗粒悬浮液 |
| JP2025530781A (ja) | 2022-08-31 | 2025-09-17 | セイル バイオメディシンズ インコーポレイテッド | 新規のイオン化可能な脂質および脂質ナノ粒子ならびにそれらの使用方法 |
| US20240174732A1 (en) | 2022-10-05 | 2024-05-30 | Flagship Pioneering Innovations V, Inc. | Nucleic acid molecules encoding trif and additional polypeptides and their use in treating cancer |
| CN121038801A (zh) | 2022-10-24 | 2025-11-28 | Ags治疗简易股份公司 | 来自微藻的细胞外囊泡、它们在鼻内施用时的生物分布及其用途 |
| KR20250099195A (ko) | 2022-10-31 | 2025-07-01 | 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 | 폴리리보뉴클레오티드를 정제하기 위한 조성물 및 방법 |
| WO2024102730A1 (en) | 2022-11-08 | 2024-05-16 | Orna Therapeutics, Inc. | Lipids and nanoparticle compositions for delivering polynucleotides |
| WO2024102762A1 (en) | 2022-11-08 | 2024-05-16 | Orna Therapeutics, Inc. | Lipids and lipid nanoparticle compositions for delivering polynucleotides |
| CN120435298A (zh) | 2022-11-08 | 2025-08-05 | 旗舰创业创新第六有限责任公司 | 用于产生环状多核糖核苷酸的组合物和方法 |
| CN120390656A (zh) | 2022-11-08 | 2025-07-29 | 欧纳医疗公司 | 环状rna组合物 |
| EP4626401A1 (en) | 2022-12-01 | 2025-10-08 | Generation Bio Co. | Stealth lipid nanoparticle compositions for cell targeting |
| WO2024119103A1 (en) | 2022-12-01 | 2024-06-06 | Generation Bio Co. | Lipid nanoparticles comprising nucleic acids and lipid-anchored polymers |
| KR20250131271A (ko) | 2022-12-01 | 2025-09-02 | 제너레이션 바이오 컴퍼니 | 신규한 폴리글리세롤-접합된 지질 및 이를 포함하는 지질 나노입자 조성물 |
| WO2024119039A2 (en) | 2022-12-01 | 2024-06-06 | Generation Bio Co. | Stealth lipid nanoparticles and uses thereof |
| CN120615126A (zh) | 2022-12-09 | 2025-09-09 | 武田药品工业株式会社 | 经修饰的免疫调节剂 |
| WO2024129988A1 (en) | 2022-12-14 | 2024-06-20 | Flagship Pioneering Innovations Vii, Llc | Compositions and methods for delivery of therapeutic agents to bone |
| EP4648794A2 (en) | 2023-01-09 | 2025-11-19 | Flagship Pioneering Innovations VII, LLC | Vaccines and related methods |
| US20240269251A1 (en) | 2023-01-09 | 2024-08-15 | Flagship Pioneering Innovations V, Inc. | Genetic switches and their use in treating cancer |
| US20240252520A1 (en) | 2023-01-09 | 2024-08-01 | Beth Israel Deaconess Medical Center, Inc. | Therapeutic agents and their use for treating chronic wounds |
| WO2024151673A2 (en) | 2023-01-09 | 2024-07-18 | President And Fellows Of Harvard College | Recombinant nucleic acid molecules and their use in wound healing |
| WO2024167885A1 (en) | 2023-02-06 | 2024-08-15 | Flagship Pioneering Innovations Vii, Llc | Immunomodulatory compositions and related methods |
| WO2024173307A2 (en) | 2023-02-13 | 2024-08-22 | Flagship Pioneering Innovation Vii, Llc | Cleavable linker-containing ionizable lipids and lipid carriers for therapeutic compositions |
| IL322378A (en) | 2023-02-17 | 2025-09-01 | Flagship Pioneering Innovations Vii Llc | DNA compositions containing modified cytosine |
| US20240285805A1 (en) | 2023-02-17 | 2024-08-29 | Flagship Pioneering Innovations Vii, Llc | Dna compositions comprising modified uracil |
| WO2024192420A1 (en) | 2023-03-15 | 2024-09-19 | Flagship Pioneering Innovations Vi, Llc | Compositions comprising polyribonucleotides and uses thereof |
| WO2024192422A1 (en) | 2023-03-15 | 2024-09-19 | Flagship Pioneering Innovations Vi, Llc | Immunogenic compositions and uses thereof |
| WO2024205657A2 (en) | 2023-03-29 | 2024-10-03 | Orna Therapeutics, Inc. | Lipids and lipid nanoparticle compositions for delivering polynucleotides |
| WO2024200826A1 (en) | 2023-03-30 | 2024-10-03 | Ose Immunotherapeutics | Lipid-based nanoparticle targeted at activated immune cells for the expression of immune cell inhibiting molecule and use thereof |
| WO2024200823A1 (en) | 2023-03-30 | 2024-10-03 | Ose Immunotherapeutics | Lipid-based nanoparticle targeted at activated immune cells for the expression of immune cell enhancing molecule and use thereof |
| AR132276A1 (es) | 2023-04-07 | 2025-06-11 | Takeda Pharmaceuticals Co | Complejo de conjugación |
| AU2024252590A1 (en) | 2023-04-12 | 2025-10-23 | Flagship Pioneering Innovations Vi, Llc | Trems for use in correction of missense mutations |
| AU2024255972A1 (en) | 2023-04-12 | 2025-10-23 | Flagship Pioneering Innovations Vi, Llc | Modified trems, compositions, and related methods thereof |
| WO2024220746A2 (en) | 2023-04-21 | 2024-10-24 | Flagship Pioneering Innovations Vii, Llc | Rnai agents targeting fatty acid synthase and related methods |
| WO2024233308A2 (en) | 2023-05-05 | 2024-11-14 | Orna Therapeutics, Inc. | Circular rna compositions and methods |
| WO2024236504A1 (en) | 2023-05-15 | 2024-11-21 | Takeda Pharmaceutical Company Limited | Sequences and methods for delivery of dna and rna |
| WO2024236361A1 (en) | 2023-05-15 | 2024-11-21 | Takeda Pharmaceutical Company Limited | Compositions and methods for delivery of nucleic acids to cells |
| WO2024243438A2 (en) | 2023-05-23 | 2024-11-28 | Omega Therapeutics, Inc. | Compositions and methods for reducing cxcl9, cxcl10, and cxcl11 gene expression |
| WO2024240962A1 (en) | 2023-05-25 | 2024-11-28 | Ethris Gmbh | Gm-csf-encoding nucleic acids, pharmaceutical compositions, methods and uses thereof |
| WO2024251108A1 (zh) * | 2023-06-07 | 2024-12-12 | 北京因诺惟康医药科技有限公司 | 可电离脂质化合物、包含其的脂质载体及应用 |
| WO2024258829A1 (en) | 2023-06-12 | 2024-12-19 | Flagship Pioneering Innovations Vii, Llc | Sars-cov-2 vaccine compositions and related methods |
| WO2025006684A1 (en) | 2023-06-28 | 2025-01-02 | Flagship Pioneering Innovations Vi, Llc | Circular polyribonucleotides encoding antifusogenic polypeptides |
| TW202516001A (zh) | 2023-07-25 | 2025-04-16 | 美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 | Ｃａｓ內切酶及相關方法 |
| WO2025027116A1 (en) | 2023-08-01 | 2025-02-06 | Institut Curie | Nanoparticles comprising nucleic acid sequences encoding cyclic gmp-amp synthase |
| WO2025042786A1 (en) | 2023-08-18 | 2025-02-27 | Flagship Pioneering Innovations Vi, Llc | Compositions comprising circular polyribonucleotides and uses thereof |
| WO2025045767A1 (en) | 2023-08-25 | 2025-03-06 | Ethris Gmbh | Stabilized lipid and lipidoid nanoparticle formulations with specific surfactant properties for enhanced pharmaceutical applications |
| WO2025049690A1 (en) | 2023-08-29 | 2025-03-06 | Orna Therapeutics, Inc. | Circular polyethylene glycol lipids |
| EP4520345A1 (en) | 2023-09-06 | 2025-03-12 | Myneo Nv | Product |
| WO2025054236A2 (en) | 2023-09-06 | 2025-03-13 | Flagship Pioneering Innovations Vii, Llc | Sars-cov-2 vaccine compositions and related methods |
| WO2025052180A2 (en) | 2023-09-07 | 2025-03-13 | Axelyf ehf. | Lipids and lipid nanoparticles |
| WO2025064475A2 (en) | 2023-09-18 | 2025-03-27 | Flagship Pioneering Innovations Vii, Llc | Ionizable lipidoid compositions and therapeutic uses thereof |
| WO2025072331A1 (en) | 2023-09-26 | 2025-04-03 | Flagship Pioneering Innovations Vii, Llc | Cas nucleases and related methods |
| WO2025096807A2 (en) | 2023-10-31 | 2025-05-08 | Flagship Pioneering Innovations Vii, Llc | Novel therapeutic dna forms |
| CN117482066B (zh) * | 2023-11-02 | 2024-08-13 | 深圳市易瑞生物技术股份有限公司 | 脂质组合物和用于脂质组合物的化合物 |
| WO2025101501A1 (en) | 2023-11-07 | 2025-05-15 | Orna Therapeutics, Inc. | Circular rna compositions |
| US20250162981A1 (en) | 2023-11-14 | 2025-05-22 | Flagship Pioneering Innovations Vii, Llc | Ionizable lipidoid compositions and therapeutic uses thereof |
| TW202523695A (zh) | 2023-11-22 | 2025-06-16 | 美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 | 用於治療非酒精性脂肪性肝病之方法及組成物 |
| WO2025117877A2 (en) | 2023-12-01 | 2025-06-05 | Flagship Pioneering Innovations Vii, Llc | Cas nucleases and related methods |
| WO2025129128A1 (en) | 2023-12-15 | 2025-06-19 | Vivasor, Inc. | Compositions and methods for non-viral delivery of therapeutic compounds |
| WO2025133115A1 (en) | 2023-12-21 | 2025-06-26 | Ose Immunotherapeutics | Lipid-based nanoparticles comprising il-35 |
| WO2025133951A1 (en) | 2023-12-21 | 2025-06-26 | Genevant Sciences Gmbh | Ionizable lipids suitable for lipid nanoparticles |
| WO2025160334A1 (en) | 2024-01-26 | 2025-07-31 | Flagship Pioneering Innovations Vii, Llc | Immunoreceptor inhibitory proteins and related methods |
| WO2025176843A1 (en) | 2024-02-21 | 2025-08-28 | Ags Therapeutics Sas | Microalgae extracellular vesicle based gene therapy vectors (mev-gtvs), their preparation, and uses thereof |
| WO2025194019A1 (en) | 2024-03-14 | 2025-09-18 | Flagship Pioneering Innovations Vii, Llc | Methods for treating liver fibrosis and non-alcoholic fatty liver disease |
| WO2025210521A1 (en) | 2024-04-04 | 2025-10-09 | Genevant Sciences Gmbh | Lipid nanoparticles for stimulating t cells |
| WO2025210520A1 (en) | 2024-04-04 | 2025-10-09 | Genevant Sciences Gmbh | Lipid nanoparticles for inducing an immunological response |
| WO2025217275A2 (en) | 2024-04-10 | 2025-10-16 | Flagship Pioneering Innovations Vii, Llc | Immune cell targeted compositions and related methods |
| WO2025240680A1 (en) | 2024-05-16 | 2025-11-20 | Flagship Pioneering Innovations Vii, Llc | Immunoreceptor inhibitory proteins and related methods |
| WO2025245188A2 (en) | 2024-05-21 | 2025-11-27 | Flagship Pioneering Innovations Vii, Llc | Methods of treating liver steatosis and non-alcoholic fatty liver disease |
| WO2025245111A1 (en) | 2024-05-22 | 2025-11-27 | Flagship Pioneering Innovations Vii, Llc | Immunoreceptor targeting proteins and related methods |
Family Cites Families (147)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
| US3901654A (en) | 1971-06-21 | 1975-08-26 | Biological Developments | Receptor assays of biologically active compounds employing biologically specific receptors |
| US3817827A (en) | 1972-03-30 | 1974-06-18 | Scott Paper Co | Soft absorbent fibrous webs containing elastomeric bonding material and formed by creping and embossing |
| US3935074A (en) | 1973-12-17 | 1976-01-27 | Syva Company | Antibody steric hindrance immunoassay with two antibodies |
| US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
| US4034074A (en) | 1974-09-19 | 1977-07-05 | The Board Of Trustees Of Leland Stanford Junior University | Universal reagent 2-site immunoradiometric assay using labelled anti (IgG) |
| US3993754A (en) | 1974-10-09 | 1976-11-23 | The United States Of America As Represented By The United States Energy Research And Development Administration | Liposome-encapsulated actinomycin for cancer chemotherapy |
| US3984533A (en) | 1975-11-13 | 1976-10-05 | General Electric Company | Electrophoretic method of detecting antigen-antibody reaction |
| US4086257A (en) | 1976-10-12 | 1978-04-25 | Sears Barry D | Phosphatidyl quaternary ammonium compounds |
| US4098876A (en) | 1976-10-26 | 1978-07-04 | Corning Glass Works | Reverse sandwich immunoassay |
| CH624011A5 (enExample) | 1977-08-05 | 1981-07-15 | Battelle Memorial Institute | |
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4452901A (en) | 1980-03-20 | 1984-06-05 | Ciba-Geigy Corporation | Electrophoretically transferring electropherograms to nitrocellulose sheets for immuno-assays |
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| US4522803A (en) | 1983-02-04 | 1985-06-11 | The Liposome Company, Inc. | Stable plurilamellar vesicles, their preparation and use |
| US4588578A (en) | 1983-08-08 | 1986-05-13 | The Liposome Company, Inc. | Lipid vesicles prepared in a monophase |
| US5208036A (en) | 1985-01-07 | 1993-05-04 | Syntex (U.S.A.) Inc. | N-(ω, (ω-1)-dialkyloxy)- and N-(ω, (ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4737323A (en) | 1986-02-13 | 1988-04-12 | Liposome Technology, Inc. | Liposome extrusion method |
| US5453566A (en) | 1986-03-28 | 1995-09-26 | Calgene, Inc. | Antisense regulation of gene expression in plant/cells |
| US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
| CA1340323C (en) | 1988-09-20 | 1999-01-19 | Arnold E. Hampel | Rna catalyst for cleaving specific rna sequences |
| GB8822492D0 (en) | 1988-09-24 | 1988-10-26 | Considine J | Apparatus for removing tumours from hollow organs of body |
| US5725871A (en) | 1989-08-18 | 1998-03-10 | Danbiosyst Uk Limited | Drug delivery compositions comprising lysophosphoglycerolipid |
| AU637800B2 (en) | 1989-08-31 | 1993-06-10 | City Of Hope | Chimeric dna-rna catalytic sequences |
| US5286634A (en) | 1989-09-28 | 1994-02-15 | Stadler Joan K | Synergistic method for host cell transformation |
| US5707644A (en) | 1989-11-04 | 1998-01-13 | Danbiosyst Uk Limited | Small particle compositions for intranasal drug delivery |
| US6753423B1 (en) | 1990-01-11 | 2004-06-22 | Isis Pharmaceuticals, Inc. | Compositions and methods for enhanced biostability and altered biodistribution of oligonucleotides in mammals |
| US5279833A (en) | 1990-04-04 | 1994-01-18 | Yale University | Liposomal transfection of nucleic acids into animal cells |
| US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
| US6365730B1 (en) | 1990-06-19 | 2002-04-02 | Gene Shears Pty. Limited | DNA-Armed ribozymes and minizymes |
| US5068120A (en) * | 1990-08-01 | 1991-11-26 | Nabisco Brands, Inc. | Amine ester derivatives as low calorie fat mimetics |
| US5789573A (en) | 1990-08-14 | 1998-08-04 | Isis Pharmaceuticals, Inc. | Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2 |
| US5672695A (en) | 1990-10-12 | 1997-09-30 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Modified ribozymes |
| DE4216134A1 (de) | 1991-06-20 | 1992-12-24 | Europ Lab Molekularbiolog | Synthetische katalytische oligonukleotidstrukturen |
| US5283185A (en) | 1991-08-28 | 1994-02-01 | University Of Tennessee Research Corporation | Method for delivering nucleic acids into cells |
| US6831166B2 (en) | 1992-10-23 | 2004-12-14 | Isis Pharmaceuticals, Inc. | Derivatized oligonucleotides having improved uptake and other properties |
| US5756353A (en) | 1991-12-17 | 1998-05-26 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol-and liposome-based delivery |
| US5652094A (en) | 1992-01-31 | 1997-07-29 | University Of Montreal | Nucleozymes |
| CA2135646A1 (en) | 1992-05-11 | 1993-11-25 | Kenneth G. Draper | Method and reagent for inhibiting viral replication |
| ATE155681T1 (de) | 1992-05-18 | 1997-08-15 | Minnesota Mining & Mfg | Einrichtung zur transmucosalen wirkstoffabgabe |
| US5792451A (en) | 1994-03-02 | 1998-08-11 | Emisphere Technologies, Inc. | Oral drug delivery compositions and methods |
| WO1994002595A1 (en) | 1992-07-17 | 1994-02-03 | Ribozyme Pharmaceuticals, Inc. | Method and reagent for treatment of animal diseases |
| IL108367A0 (en) | 1993-01-27 | 1994-04-12 | Hektoen Inst For Medical Resea | Antisense polynzcleotide inhibition of human growth factor-sensitive cancer cells |
| US5426039A (en) | 1993-09-08 | 1995-06-20 | Bio-Rad Laboratories, Inc. | Direct molecular cloning of primer extended DNA containing an alkane diol |
| US5801154A (en) | 1993-10-18 | 1998-09-01 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of multidrug resistance-associated protein |
| US5591317A (en) | 1994-02-16 | 1997-01-07 | Pitts, Jr.; M. Michael | Electrostatic device for water treatment |
| US5631359A (en) | 1994-10-11 | 1997-05-20 | Ribozyme Pharmaceuticals, Inc. | Hairpin ribozymes |
| EP1179340A3 (en) | 1994-09-30 | 2003-05-07 | INEX Pharmaceutical Corp. | Compositions for the introduction of polyanionic materials into cells |
| US5753613A (en) | 1994-09-30 | 1998-05-19 | Inex Pharmaceuticals Corporation | Compositions for the introduction of polyanionic materials into cells |
| US5885613A (en) | 1994-09-30 | 1999-03-23 | The University Of British Columbia | Bilayer stabilizing components and their use in forming programmable fusogenic liposomes |
| WO1996011266A2 (en) | 1994-10-05 | 1996-04-18 | Amgen Inc. | Method for inhibiting smooth muscle cell proliferation and oligonucleotides for use therein |
| US5783683A (en) | 1995-01-10 | 1998-07-21 | Genta Inc. | Antisense oligonucleotides which reduce expression of the FGFRI gene |
| US5580579A (en) | 1995-02-15 | 1996-12-03 | Nano Systems L.L.C. | Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers |
| IE80468B1 (en) | 1995-04-04 | 1998-07-29 | Elan Corp Plc | Controlled release biodegradable nanoparticles containing insulin |
| US5646241A (en) * | 1995-05-12 | 1997-07-08 | Quantum Materials, Inc. | Bleed resistant cyanate ester-containing compositions |
| US5981501A (en) | 1995-06-07 | 1999-11-09 | Inex Pharmaceuticals Corp. | Methods for encapsulating plasmids in lipid bilayers |
| AU723163B2 (en) | 1995-06-07 | 2000-08-17 | Tekmira Pharmaceuticals Corporation | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
| US7422902B1 (en) | 1995-06-07 | 2008-09-09 | The University Of British Columbia | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
| US5747470A (en) | 1995-06-07 | 1998-05-05 | Gen-Probe Incorporated | Method for inhibiting cellular proliferation using antisense oligonucleotides to gp130 mRNA |
| US5705385A (en) | 1995-06-07 | 1998-01-06 | Inex Pharmaceuticals Corporation | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
| US20040142895A1 (en) | 1995-10-26 | 2004-07-22 | Sirna Therapeutics, Inc. | Nucleic acid-based modulation of gene expression in the vascular endothelial growth factor pathway |
| US20030216335A1 (en) | 2001-11-30 | 2003-11-20 | Jennifer Lockridge | Method and reagent for the modulation of female reproductive diseases and conditions |
| US5998203A (en) | 1996-04-16 | 1999-12-07 | Ribozyme Pharmaceuticals, Inc. | Enzymatic nucleic acids containing 5'-and/or 3'-cap structures |
| US6713069B1 (en) | 1996-04-16 | 2004-03-30 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Compositions and methods for detecting, preventing, and treating African Hemorrhagic Fever |
| US20050119470A1 (en) | 1996-06-06 | 2005-06-02 | Muthiah Manoharan | Conjugated oligomeric compounds and their use in gene modulation |
| US6111085A (en) | 1996-09-13 | 2000-08-29 | Isis Pharmaceuticals, Inc. | Carbamate-derivatized nucleosides and oligonucleosides |
| US5739119A (en) | 1996-11-15 | 1998-04-14 | Galli; Rachel L. | Antisense oligonucleotides specific for the muscarinic type 2 acetylcholine receptor MRNA |
| US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
| DE69841002D1 (de) | 1997-05-14 | 2009-09-03 | Univ British Columbia | Hochwirksame verkapselung von nukleinsäuren in lipidvesikeln |
| US6110745A (en) | 1997-07-24 | 2000-08-29 | Inex Pharmaceuticals Corp. | Preparation of lipid-nucleic acid particles using a solvent extraction and direct hydration method |
| US6320017B1 (en) | 1997-12-23 | 2001-11-20 | Inex Pharmaceuticals Corp. | Polyamide oligomers |
| DE69906977T2 (de) | 1998-07-20 | 2004-05-19 | Protiva Biotherapeutics Inc., Burnaby | In liposomen verkapselte nukleinsäurekomplexe |
| AU783647B2 (en) | 1999-04-20 | 2005-11-17 | University Of British Columbia, The | Cationic peg-lipids and methods of use |
| US6852334B1 (en) | 1999-04-20 | 2005-02-08 | The University Of British Columbia | Cationic peg-lipids and methods of use |
| CZ20021029A3 (cs) | 1999-08-27 | 2002-08-14 | Inex Pharmaceuticals Corp. | Kompozice a její pouľití pro stimulaci sekrece cytokinů a indukci imunitní odpovědi |
| US7491805B2 (en) | 2001-05-18 | 2009-02-17 | Sirna Therapeutics, Inc. | Conjugates and compositions for cellular delivery |
| US7833992B2 (en) | 2001-05-18 | 2010-11-16 | Merck Sharpe & Dohme | Conjugates and compositions for cellular delivery |
| US8202979B2 (en) | 2002-02-20 | 2012-06-19 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid |
| US7189705B2 (en) | 2000-04-20 | 2007-03-13 | The University Of British Columbia | Methods of enhancing SPLP-mediated transfection using endosomal membrane destabilizers |
| ES2307568T3 (es) | 2000-12-08 | 2008-12-01 | Coley Pharmaceutical Gmbh | Acidos nucleicos de tipo cpg y metodos de uso de los mismos. |
| US7053150B2 (en) | 2000-12-18 | 2006-05-30 | Nektar Therapeutics Al, Corporation | Segmented polymers and their conjugates |
| TW593427B (en) | 2000-12-18 | 2004-06-21 | Nektar Therapeutics Al Corp | Synthesis of high molecular weight non-peptidic polymer derivatives |
| US20030077829A1 (en) | 2001-04-30 | 2003-04-24 | Protiva Biotherapeutics Inc.. | Lipid-based formulations |
| US7109165B2 (en) | 2001-05-18 | 2006-09-19 | Sirna Therapeutics, Inc. | Conjugates and compositions for cellular delivery |
| US20070173473A1 (en) | 2001-05-18 | 2007-07-26 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of proprotein convertase subtilisin Kexin 9 (PCSK9) gene expression using short interfering nucleic acid (siNA) |
| US20050282188A1 (en) | 2001-05-18 | 2005-12-22 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA) |
| US20030130186A1 (en) | 2001-07-20 | 2003-07-10 | Chandra Vargeese | Conjugates and compositions for cellular delivery |
| GB0118517D0 (en) * | 2001-07-30 | 2001-09-19 | Mitsubishi Tokyo Pharm Inc | Compound |
| DE10163098B4 (de) | 2001-10-12 | 2005-06-02 | Alnylam Europe Ag | Verfahren zur Hemmung der Replikation von Viren |
| AU2003207708A1 (en) | 2002-02-20 | 2003-09-09 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of map kinase genes |
| EP1476552A2 (en) | 2002-02-22 | 2004-11-17 | Strebhardt, Klaus, Prof. Dr. | Agent for inhibiting development or progress of proliferative diseases and especially cancer diseases and pharmaceutical composition containing said agent |
| EP2823809B1 (en) | 2002-06-28 | 2016-11-02 | Protiva Biotherapeutics Inc. | Method and apparatus for producing liposomes |
| DE60326961D1 (de) | 2002-07-26 | 2009-05-14 | Novartis Vaccines & Diagnostic | Modifizierte kleine irns moleküle und methoden zu deren anwendung |
| WO2006006948A2 (en) | 2002-11-14 | 2006-01-19 | Dharmacon, Inc. | METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY |
| EP2213738B1 (en) | 2002-11-14 | 2012-10-10 | Dharmacon, Inc. | siRNA molecules targeting Bcl-2 |
| US20040167090A1 (en) | 2003-02-21 | 2004-08-26 | Monahan Sean D. | Covalent modification of RNA for in vitro and in vivo delivery |
| US20040185559A1 (en) | 2003-03-21 | 2004-09-23 | Isis Pharmaceuticals Inc. | Modulation of diacylglycerol acyltransferase 1 expression |
| CA2488224A1 (en) | 2003-04-03 | 2004-10-21 | Alnylam Pharmaceuticals, Inc. | Irna conjugates |
| CA2521464C (en) | 2003-04-09 | 2013-02-05 | Alnylam Pharmaceuticals, Inc. | Irna conjugates |
| EP2660322A3 (en) | 2003-04-17 | 2013-11-13 | Alnylam Pharmaceuticals Inc. | Modified iRNA agents |
| EP2567693B1 (en) | 2003-07-16 | 2015-10-21 | Protiva Biotherapeutics Inc. | Lipid encapsulated interfering RNA |
| US7825235B2 (en) | 2003-08-18 | 2010-11-02 | Isis Pharmaceuticals, Inc. | Modulation of diacylglycerol acyltransferase 2 expression |
| EP1664316B1 (en) | 2003-09-15 | 2012-08-29 | Protiva Biotherapeutics Inc. | Polyethyleneglycol-modified lipid compounds and uses thereof |
| US20070265220A1 (en) | 2004-03-15 | 2007-11-15 | City Of Hope | Methods and compositions for the specific inhibition of gene expression by double-stranded RNA |
| EP1742958B1 (en) | 2004-03-15 | 2017-05-17 | City of Hope | Methods and compositions for the specific inhibition of gene expression by double-stranded rna |
| CA2569664C (en) | 2004-06-07 | 2013-07-16 | Protiva Biotherapeutics, Inc. | Lipid encapsulated interfering rna |
| JP4764426B2 (ja) | 2004-06-07 | 2011-09-07 | プロチバ バイオセラピューティクス インコーポレイティッド | カチオン性脂質および使用方法 |
| US20090170794A1 (en) | 2004-09-10 | 2009-07-02 | Somagenics Inc. | Small interfering rnas that efficiently inhibit viral expression and methods of use thereof |
| NZ554214A (en) | 2004-09-24 | 2009-10-30 | Alnylam Pharmaceuticals Inc | Rnai modulation of apob and uses thereof |
| WO2006053430A1 (en) | 2004-11-17 | 2006-05-26 | Protiva Biotherapeutics, Inc. | Sirna silencing of apolipoprotein b |
| AU2006336384B2 (en) | 2005-02-14 | 2010-12-16 | Sirna Therapeutics, Inc. | Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules |
| US7404969B2 (en) | 2005-02-14 | 2008-07-29 | Sirna Therapeutics, Inc. | Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules |
| EP1937213B1 (en) | 2005-07-27 | 2017-10-25 | Protiva Biotherapeutics Inc. | Systems and methods for manufacturing liposomes |
| WO2007048046A2 (en) | 2005-10-20 | 2007-04-26 | Protiva Biotherapeutics, Inc. | Sirna silencing of filovirus gene expression |
| EP2395012B8 (en) | 2005-11-02 | 2018-06-06 | Arbutus Biopharma Corporation | Modified siRNA molecules and uses thereof |
| WO2007056861A1 (en) | 2005-11-18 | 2007-05-24 | Protiva Biotherapeutics, Inc. | Sirna silencing of influenza virus gene expression |
| GB0605900D0 (en) * | 2006-03-23 | 2006-05-03 | Lipigen As | Modulators of nuclear receptors |
| AU2007249329C1 (en) | 2006-05-11 | 2011-03-24 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the PCSK9 gene |
| US8598333B2 (en) | 2006-05-26 | 2013-12-03 | Alnylam Pharmaceuticals, Inc. | SiRNA silencing of genes expressed in cancer |
| ES2611924T3 (es) | 2006-10-03 | 2017-05-11 | Arbutus Biopharma Corporation | Formulaciones que contienen lípidos |
| KR100996975B1 (ko) * | 2007-08-24 | 2010-11-29 | 한국화학연구원 | 혈류 내 순환시간 증가를 위한 단백질로 수식된 리포솜 및이의 제조방법 |
| CA2710713C (en) | 2007-12-27 | 2017-09-19 | Protiva Biotherapeutics, Inc. | Silencing of polo-like kinase expression using interfering rna |
| JP5749494B2 (ja) * | 2008-01-02 | 2015-07-15 | テクミラ ファーマシューティカルズ コーポレイション | 核酸の送達のための改善された組成物および方法 |
| CA2711236A1 (en) * | 2008-01-02 | 2009-07-16 | Alnylam Pharmaceuticals, Inc. | Screening method for selected amino lipid-containing compositions |
| WO2009127060A1 (en) | 2008-04-15 | 2009-10-22 | Protiva Biotherapeutics, Inc. | Novel lipid formulations for nucleic acid delivery |
| JP2011516094A (ja) | 2008-04-15 | 2011-05-26 | プロチバ バイオセラピューティクス インコーポレイティッド | 干渉ｒｎａを用いたｃｓｎ５遺伝子発現のサイレンシング方法 |
| KR101647334B1 (ko) | 2008-07-10 | 2016-08-10 | 세리나 쎄라퓨틱스, 인코포레이티드 | 불활성 말단기를 가진 폴리옥사졸린, 보호된 개시기로부터 제조된 폴리옥사졸린 및 그와 관련된 화합물 |
| KR100996976B1 (ko) | 2008-08-27 | 2010-11-29 | 현대엔지니어링 주식회사 | 장수명 ｍｔｏ 반응용 촉매 및 이의 제조방법 |
| ES2475065T3 (es) | 2008-10-09 | 2014-07-10 | Tekmira Pharmaceuticals Corporation | Aminol�pidos mejorados y métodos para la administración de ácidos nucleicos |
| ES2993911T3 (en) * | 2008-11-10 | 2025-01-13 | Arbutus Biopharma Corp | Novel lipids and compositions for the delivery of therapeutics |
| DK3431076T3 (da) * | 2009-06-10 | 2021-12-20 | Arbutus Biopharma Corp | Forbedret lipidformulering |
| ES2613498T3 (es) | 2009-07-01 | 2017-05-24 | Protiva Biotherapeutics Inc. | Nuevas formulaciones de lípidos para el suministro de agentes terapéuticos a tumores sólidos |
| US8569256B2 (en) * | 2009-07-01 | 2013-10-29 | Protiva Biotherapeutics, Inc. | Cationic lipids and methods for the delivery of therapeutic agents |
| AU2010330814B2 (en) * | 2009-12-18 | 2017-01-12 | Acuitas Therapeutics Inc. | Methods and compositions for delivery of nucleic acids |
| WO2011143230A1 (en) * | 2010-05-10 | 2011-11-17 | Alnylam Pharmaceuticals | Methods and compositions for delivery of active agents |
| US20130123338A1 (en) | 2010-05-12 | 2013-05-16 | Protiva Biotherapeutics, Inc. | Novel cationic lipids and methods of use thereof |
| US10077232B2 (en) * | 2010-05-12 | 2018-09-18 | Arbutus Biopharma Corporation | Cyclic cationic lipids and methods of use |
| WO2011141703A1 (en) * | 2010-05-12 | 2011-11-17 | Protiva Biotherapeutics Inc. | Compositions and methods for silencing apolipoprotein b |
| WO2011153120A1 (en) * | 2010-06-04 | 2011-12-08 | Merck Sharp & Dohme Corp. | Novel low molecular weight cationic lipids for oligonucleotide delivery |
| US8466122B2 (en) * | 2010-09-17 | 2013-06-18 | Protiva Biotherapeutics, Inc. | Trialkyl cationic lipids and methods of use thereof |
| JP2013545727A (ja) * | 2010-10-21 | 2013-12-26 | メルク・シャープ・アンド・ドーム・コーポレーション | オリゴヌクレオチド送達用の新規低分子量カチオン性脂質 |
| AU2013222179B2 (en) | 2012-02-24 | 2017-08-24 | Arbutus Biopharma Corporat ion | Trialkyl cationic lipids and methods of use thereof |
| US9744103B1 (en) | 2013-03-08 | 2017-08-29 | Chad Ricker | Infant teething apparatus |
| CN105555757A (zh) | 2013-07-23 | 2016-05-04 | 普洛体维生物治疗公司 | 用于递送信使rna的组合物和方法 |
| WO2017015504A1 (en) | 2015-07-21 | 2017-01-26 | Scheibel Steven Frederick | Treatment and prevention of anal conditions |
-
2013
- 2013-02-22 AU AU2013222179A patent/AU2013222179B2/en active Active
- 2013-02-22 EP EP18193953.9A patent/EP3473611B1/en active Active
- 2013-02-22 DK DK13709634.3T patent/DK2817287T3/da active
- 2013-02-22 CA CA2865412A patent/CA2865412C/en active Active
- 2013-02-22 ES ES13709634T patent/ES2702874T3/es active Active
- 2013-02-22 CN CN201910048388.5A patent/CN110003030A/zh active Pending
- 2013-02-22 KR KR1020217010379A patent/KR102384791B1/ko active Active
- 2013-02-22 WO PCT/US2013/027469 patent/WO2013126803A1/en not_active Ceased
- 2013-02-22 HU HUE13709634A patent/HUE041494T2/hu unknown
- 2013-02-22 SI SI201331293T patent/SI2817287T1/sl unknown
- 2013-02-22 RU RU2014138476A patent/RU2718053C2/ru active
- 2013-02-22 MX MX2014010211A patent/MX356904B/es active IP Right Grant
- 2013-02-22 UA UAA201410393A patent/UA120026C2/uk unknown
- 2013-02-22 US US14/380,536 patent/US9352042B2/en active Active
- 2013-02-22 EP EP13709634.3A patent/EP2817287B1/en active Active
- 2013-02-22 KR KR1020147026598A patent/KR102075810B1/ko active Active
- 2013-02-22 BR BR112014020824-7A patent/BR112014020824B1/pt active IP Right Grant
- 2013-02-22 SG SG11201405157PA patent/SG11201405157PA/en unknown
- 2013-02-22 EP EP21202091.1A patent/EP3988104A1/en not_active Withdrawn
- 2013-02-22 CN CN201380020104.2A patent/CN104321304A/zh active Pending
- 2013-02-22 LT LTEP13709634.3T patent/LT2817287T/lt unknown
- 2013-02-22 ES ES18193953T patent/ES2898912T3/es active Active
- 2013-02-22 PL PL13709634T patent/PL2817287T3/pl unknown
- 2013-02-22 JP JP2014558898A patent/JP6275655B2/ja active Active
- 2013-02-22 KR KR1020207003227A patent/KR102239887B1/ko active Active
- 2013-02-22 RU RU2020111326A patent/RU2020111326A/ru unknown
- 2013-02-22 KR KR1020227011265A patent/KR20220045089A/ko not_active Ceased
- 2013-02-22 RS RS20181562A patent/RS58077B1/sr unknown
- 2013-02-22 MX MX2018006897A patent/MX392812B/es unknown
- 2013-02-22 HR HRP20182156TT patent/HRP20182156T1/hr unknown
- 2013-02-22 PT PT13709634T patent/PT2817287T/pt unknown
- 2013-02-22 NZ NZ700075A patent/NZ700075A/en unknown
-
2014
- 2014-08-22 MX MX2022006512A patent/MX2022006512A/es unknown
- 2014-08-22 PH PH12014501901A patent/PH12014501901B1/en unknown
- 2014-08-24 IL IL234266A patent/IL234266B/en active IP Right Grant
- 2014-09-19 ZA ZA2014/06896A patent/ZA201406896B/en unknown
-
2016
- 2016-05-09 US US15/150,016 patent/US10561732B2/en active Active
-
2017
- 2017-12-11 JP JP2017236756A patent/JP6789918B2/ja active Active
-
2019
- 2019-01-03 CY CY20191100004T patent/CY1121232T1/el unknown
-
2020
- 2020-01-30 US US16/776,950 patent/US11395854B2/en active Active
- 2020-08-25 IL IL276924A patent/IL276924A/en unknown
- 2020-11-04 JP JP2020184356A patent/JP7110297B2/ja active Active
-
2022
- 2022-02-27 IL IL290931A patent/IL290931A/en unknown
- 2022-06-17 US US17/843,188 patent/US20230109183A1/en not_active Abandoned
- 2022-07-20 JP JP2022115626A patent/JP2022140533A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015509505A5 (enExample) | ||
| RU2020111326A (ru) | Триалкил катионные липиды и способы их использования | |
| CA2532228C (en) | Lipid encapsulated interfering rna | |
| JP2021073263A (ja) | Ｒｎａ送達のためのイオン化可能なカチオン性脂質 | |
| CA2569664C (en) | Lipid encapsulated interfering rna | |
| JP2019508371A5 (enExample) | ||
| JP2020514366A5 (enExample) | ||
| JP2011507534A5 (enExample) | ||
| JP2011516586A5 (enExample) | ||
| CA2979998A1 (en) | Compositions and methods for treating hypertriglyceridemia | |
| JP7325327B2 (ja) | インフュージョンリアクションを改善するための方法 | |
| JP6389477B2 (ja) | カチオン性脂質 | |
| JPWO2020061367A5 (enExample) | ||
| JP2025505971A (ja) | 脂質ナノ粒子用のイオン化できるカチオン性脂質 | |
| JP2024105468A (ja) | Ｂ型肝炎を治療するための治療用組成物及び方法 | |
| EP3634431A1 (en) | Therapeutic compositions and methods for treating hepatitis b | |
| TW201919653A (zh) | 用於治療ｂ型肝炎之治療組合物及方法 | |
| US20070054873A1 (en) | Glucocorticoid modulation of nucleic acid-mediated immune stimulation | |
| US20240417738A1 (en) | Immunotherapies for the treatment of cancer | |
| WO2018225873A1 (ja) | 核酸含有ナノ粒子 | |
| WO2024220742A1 (en) | Conjugated polyethyleneimine compounds and compositions, and uses thereof for the treatment of atherosclerosis, cardiovascular, and lung disease | |
| WO2024209011A1 (en) | Nanoparticle compositions comprising one or more variants of poly(d,l-lactic- co-glycolic acid) |